Characterization of the immune status of patients becomes increasingly important to personalize cancer treatments. The required extraction of information and biological insights from tissue slides remains challenging because of the broad heterogeneity of tumor and immune cells embedded in the complex tumor microenvironment. Thus, the analysis requires expert insights as well as standardized methods.
Definiens has developed a standardized multiplex immunohistochemistry (mIHC) assay (IO panel) to profile the immune status of patient tumors into biologically meaningful and clinically actionable categories.
In this webinar, our speaker will discuss:
- How to study the functional interaction between the immune system and the individual cancer using next-generation image mining and data analysis software for real-time analysis of huge multiplexed data sets
- How this approach enables the spatial analysis and aggregation of multiplexed information in heterogeneous tissue
The statistical analysis and evaluation combined with interactive data visualization and reporting are expected to support better patient stratification towards different immunotherapies or their combinations. The integration of genomic (e.g. mutational load) data is supported as well as the integration of any other -omics data.
Dr. Svenja Lippok, Product Marketing Manager, Definiens AG
Svenja Lippok graduated in Physics with a Diploma degree from the Ludwig-Maximilians University (LMU) in Munich. She earned her PhD in Munich with her field of study on new diagnostic devices for blood coagulation.
She joined Definiens’ Professional Services team in 2015 providing automated image and data analysis services on histopathological images. Recently, she moved to the Product Marketing team where she is responsible for the IO panel.Message Presenter
Who Should Attend?
This webinar will be ideal for Medical, Pharmaceutical, Biotech and Diagnostics executives, for directors and vice presidents of therapeutic areas and Chief Scientific, Medical and Executive Officers. It will also be informative for lab and study directors, and medical directors.
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.